Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (121-130 of 168) with videos related to

Pageof 17
Sort By:
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomesGiuseppe Galletti, Ahmed Halima, Ada Gjyrezi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial CancerMichael Karass, Rohan Bareja, Ethan Shelkey, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Communications Biology|June 25, 2021
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stageAda Gjyrezi, Giuseppe Galletti, Jiaren Zhang, et al.
European Urology|September 18, 2012
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneityHimisha Beltran, Roman Yelensky, Garrett M Frampton, et al.
Molecular Cancer Therapeutics|March 5, 2020
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based ChemotherapyVincenza Conteduca, Sheng-Yu Ku, Loredana Puca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
JCO Precision Oncology|September 3, 2019
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden DistributionEvan M Fernandez, Kenneth Eng, Shaham Beg, et al.
Journal of Translational Medicine|January 9, 2007
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanomaElsa F Velazquez, Molly Yancovitz, Anna Pavlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
Pageof 17

Showing results (121-130 of 168) with videos related to

Sort By:
Pageof 17
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Transferrin receptor-based circulating tumor cell enrichment provides a snapshot of the molecular landscape of solid tumors and correlates with clinical outcomesGiuseppe Galletti, Ahmed Halima, Ada Gjyrezi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial CancerMichael Karass, Rohan Bareja, Ethan Shelkey, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Communications Biology|June 25, 2021
Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stageAda Gjyrezi, Giuseppe Galletti, Jiaren Zhang, et al.
European Urology|September 18, 2012
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneityHimisha Beltran, Roman Yelensky, Garrett M Frampton, et al.
Molecular Cancer Therapeutics|March 5, 2020
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based ChemotherapyVincenza Conteduca, Sheng-Yu Ku, Loredana Puca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate CancerRahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
JCO Precision Oncology|September 3, 2019
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden DistributionEvan M Fernandez, Kenneth Eng, Shaham Beg, et al.
Journal of Translational Medicine|January 9, 2007
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanomaElsa F Velazquez, Molly Yancovitz, Anna Pavlick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
Pageof 17